NL
AVXL icon

NWAM LLC’s Anavex Life Sciences AVXL Stock Holding History

NWAM LLC’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-870,796
Closed -$4.37M – 628
2025
Q4 		$4.37M Sell
870,796
-3,487
-0.4% -$21.4K 0.24% 100
2025
Q3 		$8.18M Sell
874,283
-150,196
-15% -$1.52M 0.44% 46
2025
Q2 		$11.6M Buy
1,024,479
+24,128
+2% +$206K 0.67% 26
2025
Q1 		$8.58M Buy
1,000,351
+87,300
+10% +$824K 0.74% 19
2024
Q4 		$9.81M Buy
913,051
+2,575
+0.3% +$19.8K 0.61% 36
2024
Q3 		$5.17M Buy
+910,476
New +$5.25M 0.32% 75
2024
Q2 		– Sell
-836,730
Closed -$3.21M – 180
2024
Q1 		$3.21M Buy
836,730
+38,437
+5% +$216K 0.26% 86
2023
Q4 		$7.43M Buy
798,293
+77,303
+11% +$532K 0.6% 30
2023
Q3 		$4.72M Buy
720,990
+86,390
+14% +$688K 0.48% 43
2023
Q2 		$5.16M Buy
634,600
+86,363
+16% +$740K 0.42% 51
2023
Q1 		$4.7M Buy
+548,237
New +$5.47M 0.48% 47

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

NWAM LLC's AVXL Position: Q1 2026 in Review

NWAM LLC sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 870,796 shares — an estimated $4.37M sold.

NWAM LLC first reported a position in AVXL in Q1 2023 and held it in 11 quarters. The position peaked at $11.6M in Q2 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • NWAM LLC reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
  • NWAM LLC sold 870,796 Anavex Life Sciences shares in Q1 2026, an estimated $4.37M.
  • NWAM LLC first reported a position in Anavex Life Sciences in Q1 2023 and held it in 11 quarters.
  • NWAM LLC's Anavex Life Sciences position peaked at $11.6M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on NWAM LLC's 13F filing for Q1 2026, filed 4 May 2026.